BIOC Stock Overview
GlaxoSmithKline S.A.E. engages in the production of pharmaceutical chemicals in Egypt.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 1/6 |
| Financial Health | 6/6 |
| Dividends | 2/6 |
GlaxoSmithKline S.A.E Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ج.م32.37 |
| 52 Week High | ج.م47.50 |
| 52 Week Low | ج.م26.26 |
| Beta | 0.93 |
| 1 Month Change | 4.62% |
| 3 Month Change | -15.35% |
| 1 Year Change | -10.33% |
| 3 Year Change | 23.79% |
| 5 Year Change | n/a |
| Change since IPO | 247.32% |
Recent News & Updates
Recent updates
Shareholder Returns
| BIOC | EG Pharmaceuticals | EG Market | |
|---|---|---|---|
| 7D | 3.3% | 0.8% | -1.0% |
| 1Y | -10.3% | 32.1% | 60.7% |
Return vs Industry: BIOC underperformed the EG Pharmaceuticals industry which returned 35.9% over the past year.
Return vs Market: BIOC underperformed the EG Market which returned 67.8% over the past year.
Price Volatility
| BIOC volatility | |
|---|---|
| BIOC Average Weekly Movement | 8.0% |
| Pharmaceuticals Industry Average Movement | 5.6% |
| Market Average Movement | 8.7% |
| 10% most volatile stocks in EG Market | 13.3% |
| 10% least volatile stocks in EG Market | 4.8% |
Stable Share Price: BIOC's share price has been volatile over the past 3 months.
Volatility Over Time: BIOC's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1981 | n/a | Hassan Fahmi | www.gsk.com/en-gb/contact-us/worldwide/egypt |
GlaxoSmithKline S.A.E. engages in the production of pharmaceutical chemicals in Egypt. It is also involved in the manufacture of medical preparations and cosmetics. The company was founded in 1981 and is headquartered in New Cairo City, Egypt.
GlaxoSmithKline S.A.E Fundamentals Summary
| BIOC fundamental statistics | |
|---|---|
| Market cap | ج.م2.70b |
| Earnings (TTM) | ج.م74.10m |
| Revenue (TTM) | ج.م2.24b |
36.5x
P/E Ratio1.2x
P/S RatioIs BIOC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BIOC income statement (TTM) | |
|---|---|
| Revenue | ج.م2.24b |
| Cost of Revenue | ج.م1.45b |
| Gross Profit | ج.م789.12m |
| Other Expenses | ج.م715.03m |
| Earnings | ج.م74.10m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.89 |
| Gross Margin | 35.23% |
| Net Profit Margin | 3.31% |
| Debt/Equity Ratio | 0% |
How did BIOC perform over the long term?
See historical performance and comparison